American Association for Cancer Research
23266066cir160201-sup-169928_1_supp_3656358_qd3jq4.png (90.25 kB)

Supplementary Table 2 from Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

Download (90.25 kB)
posted on 2023-04-03, 23:10 authored by Margaretha G.M. Roemer, Ranjana H. Advani, Robert A. Redd, Geraldine S. Pinkus, Yasodha Natkunam, Azra H. Ligon, Courtney F. Connelly, Christine J. Pak, Christopher D. Carey, Sarah E. Daadi, Bjoern Chapuy, Daphne de Jong, Richard T. Hoppe, Donna S. Neuberg, Margaret A. Shipp, Scott J. Rodig

Outcome (progression-free survival) - Cox multivariable models for beta2M



Miller Family Fund

Leukemia & Lymphoma Society

International Immune OncologyNetwork of Bristol-Myers Squibb

Center for Immuno-Oncology



In classical Hodgkin lymphoma (cHL), malignant Hodgkin Reed–Sternberg (HRS) cells evade antitumor immunity by multiple mechanisms, including perturbed antigen presentation and enhanced PD-1 signaling. HRS cell expression of the PD-1 ligands is attributable, in part, to copy number alterations of 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2). Amplification of PD-L1/PD-L2 is associated with advanced clinical stage and inferior progression-free survival (PFS) following first-line (induction) therapy. The relationships between altered expression of β2-microglobulin (β2M), MHC class I, and MHC class II by HRS cells, PD-L1/PD-L2 amplification, and clinical outcome in cHL are poorly defined. We assessed these variables in diagnostic biopsy specimens from 108 patients with cHL who received uniform treatment and had long-term follow-up and found decreased/absent expression of β2M/MHC class I in 79% (85/108) and decreased/absent expression of MHC class II in 67% (72/108) of cases. Patients with decreased/absent β2M/MHC class I had shorter PFS, independent of PD-L1/PD-L2 amplification and advanced stage. Decreased or absent MHC class II was unrelated to outcome. These results suggest that MHC class I–mediated antigen presentation by HRS cells is an important component of the biological response to standard chemo/radiotherapy. The paucity of β2M/MHC class I expression on HRS cells also prompts speculation regarding alternative mechanisms of action of PD-1 blockade in cHL. Cancer Immunol Res; 4(11); 910–6. ©2016 AACR.

Usage metrics

    Cancer Immunology Research



    Ref. manager